Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients

International Urology and Nephrology

Volumn 45, Issue 1, 2013, Pages 207-214

  Yamashita, Tetsuri ^a   Okano, Kazuhiro ^a   Tsuruta, Yuki ^a   Akiba, Takashi ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardiovascular disease; Hemodialysis; Osteocalcin

Indexed keywords

BIOLOGICAL MARKER; OSTEOCALCIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HUMAN; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOCALCIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84873412624     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0156-6     Document Type: Article

References (28)

1. Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990-1047
2. Stein GS, Lian JB (1993) Molecular mechanism mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14:424-442
3. Urena P, De Vernejoul MC (1999) Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141-2156
4. Malluche HH, Faugere MC, Fanti P, Price PA (1984) Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 26:869-874
5. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhan Z, Kim JK, Mauvais Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469
6. Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates b-cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci 105:5266-5270
7. Wolf G (2008) Energy regulation by the skeleton. Nutr Rev 66:229-233
8. Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T (2011) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 22:187-194
9. Yeap BB, Chubb SA, Flicker L, McCaul KA, Ebeling PR, Norman PE (2010) Reduced serum total osteocalcin is associated with metabolic syndrome in older men through its association with hyperglycemia, waist circumference and serum triglycerides. Eur J Endocrinol 163:265-272
10. Rostand SG, Drueke TB (1999) Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56:383-392
11. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218
12. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793-1800
13. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CS, Whellan D, Shama K (2007) A1c and survival in maintenance hemodialysis patients. Diabetes Care 30:1049-1055
14. Tsujimoto Y, Ishimura E, Tahara H, Kakiya R, Koyama H, Emoto M, Shoji T, Inaba M, Kishimoto H, Tabata T, Nishizawa Y (2009) Poor glycemic control is a significant predictor of cardiovascular events in chronic hemodialysis patients with diabetes. Ther Apher Dial 13:358-365
15. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y (2002) Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13:1894-1900
16. Nakatsuka K, Miki T, Nishizawa Y, Tabata T, Inoue T, Morii H, Ogata E (1991) Circulating bone Gla-protein in end-stage renal disease determined by newly developed two-site immunoradiometric assay. Contrib Nephrol 90:147-154
17. Maseters PW, Jones RG, Purves DA, Cooper EH, Cooney JM (1994) Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 40:358-363
18. Rached MT, Kode A, Silva BC, Jung DY, Gray S, Onq H, Paik JH, DePinho RA, Kim JK, Karsenty G, Kousteni S (2010) FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation in osteoblasts in mice. J Clin Invest 120:357-368
19. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al (2008) High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 74:655-663
20. Epstein S, Traberg H, Raja R et al (1985) Serum and dialysate osteocalcin in hemodialysis and peritoneal dialysis patients and after renal transplantation. J Clin Endocrinol Metab 60:1253-1256
21. Yeap BB, Chubb SAP, Flicker L, McCaul KA, Ebeling PR, Hankey GJ, Beilby JP, Norman PE (2012) Associations of total with all-cause and cardiovascular mortality in older men:the health in men study. Osteoporos Int 23(2):599-606
22. Morishita T, Nomura M, Hanaoka M, Saruta T, Matsuo T, Tsukamoto Y (2000) A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in hemodialysed patients. Nephrol Dial Transplant 15:659-667
23. Frazao JM, Martins P (2009) Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens 18:303-307
24. Price PA, Williamson MK, Lothringer JW (1981) Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Bio Chem256:12760-12766
25. Hwang YC, Jeong IK, Ahn KJ, Chung HY (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced b-cell function in middleaged male subjects. Diabetes Metab Res Rev 25:768-772
26. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100: 2473-2476
27. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141
28. Rao M, Li L, Tighiouart H (2008) Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 23:2619-2628